DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026)
DBV Technologies (DBVT) reported Income from Continuing Operations of 47600000.0 for Q1 2026, down 75.65% year-over-year from 195448484.85 in Q1 2025, and down 6.18% quarter-over-quarter from 44829000.0 in Q4 2025.
DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Income from Continuing Operations data on file, last reported at 47600000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 47600000.0, down 75.65% year-over-year; the trailing twelve-month figure through Mar 2026 was 167468000.0 (down 47.32% YoY), and the FY2025 annual result was 146947000.0, down 28.99% from the prior year.
- Income from Continuing Operations retreated to 47600000.0 in Q1 2026 per DBVT's latest filing, from 44829000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 11186000.0 in Q4 2023 and troughed at 47600000.0 in Q1 2026.
- A 5-year average of 28087352.94 and a median of 27100000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 187.02% in 2022, then surged 71.49% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 39241000.0 in 2022, then surged by 71.49% to 11186000.0 in 2023, then plunged by 105.75% to 23015000.0 in 2024, then plunged by 94.78% to 44829000.0 in 2025, then declined by 6.18% to 47600000.0 in 2026.
- Business Quant data shows DBVT's Income from Continuing Operations at 47600000.0 in Q1 2026, 44829000.0 in Q4 2025, and 33164000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -47.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.88 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |
| Jun 30, 2021 | -30.65 Mn |